



www.MedChemExpress.com

Inhibitors, Agonists, Screening Libraries

Src

Src family kinase (SFK) is a family of non-receptor tyrosine kinases including nine members: Src, Yes, Fyn, and Fgr, forming the SrcA subfamily, Lck, Hck, Blk, and Lyn in the SrcB subfamily, and Frk in its own subfamily. In immune cells, Src-family kinases (SFKs) have been implicated as critical regulators of a large number of intracellular signaling pathways. Src-family kinases (SFKs) occupy a proximal position in numerous signaling transduction cascades including those emanating from the T and B cell antigen receptors, Fc receptors, growth factor receptors, cytokine receptors, and integrins. In addition to these positive regulatory roles, Src-family kinases (SFKs) can also function as negative regulators of cellular signaling by phosphorylating immunoreceptor tyrosine-based inhibitory motifs (ITIMs) on inhibitory receptors, resulting in recruitment and activation of inhibitory molecules such as the phosphatases SHP-1 and SH2 containing 5' inositol phosphatase (SHIP-1).


Src Inhibitors & Activators

1-Naphthyl PP1

(1-NA-PP 1)

Cat. No.: HY-13941

1-Naphthyl PP1 (1-NA-PP 1) is a selective inhibitor of **src** family kinases. 1-Naphthyl PP1 inhibits v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC_{50} s of 1.0, 0.6, 0.6, 18 and 22 μ M, respectively.




Purity: 98.77%
Clinical Data: No Development Reported
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

1-Naphthyl PP1 hydrochloride

(1-NA-PP 1 hydrochloride)

Cat. No.: HY-13941B

1-Naphthyl PP1 hydrochloride (1-NA-PP 1 hydrochloride) is a selective inhibitor of **src** family kinases. 1-Naphthyl PP1 hydrochloride inhibits v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC_{50} s of 1.0, 0.6, 0.6, 18 and 22 μ M, respectively.




Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

1-NM-PP1

(PP1 Analog II)

Cat. No.: HY-13942

1-NM-PP1, a cell-permeable PP1 analog, is a potent **Src** family kinases inhibitor with IC_{50} s of 4.3 nM and 3.2 nM for v-Src-as1 and c-Fyn-as1, respectively.




Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg

7-Hydroxy-4-chromone

(7-Hydroxychromone)

Cat. No.: HY-N6596

7-Hydroxychromone is a **Src** kinase inhibitor with an IC_{50} of <300 μ M.




Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM \times 1 mL, 50 mg

A 419259 trihydrochloride

(RK 20449 trihydrochloride)

Cat. No.: HY-15764A

A 419259 trihydrochloride is a **Src** family kinases inhibitor with IC_{50} s of 9 nM, 3 nM and 3 nM for **Src**, **Lck** and **Lyn**, respectively.




Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg

A-770041

Cat. No.: HY-11011

A-770041 is selective and orally active **Src**-family Lck inhibitor; A-770041 is a 147 nM inhibitor of Lck (1 mM ATP) and is 300-fold selective against Fyn, the other **Src** family kinase involved in T-cell signaling.




Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM \times 1 mL, 5 mg, 10 mg

Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH

Cat. No.: HY-P1200

Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH (compound 1) is a high-affinity pentapeptide to bind to the **src** SH2 domain ($IC_{50} \approx 1$ μ M).

Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH is an inhibitor for **src** SH3-SH2:phosphoprotein interactions.




Purity: $>98\%$
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA

Cat. No.: HY-P1200A

Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA (compound 1) is a high-affinity pentapeptide to bind to the **src** SH2 domain ($IC_{50} \approx 1$ μ M).

Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA is an inhibitor for **src** SH3-SH2:phosphoprotein interactions.




Purity: $>98\%$
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AD80

Cat. No.: HY-101963

AD80, a multikinase inhibitor, inhibits **RET**, **RAF**, **SRK** and **S6K**, with greatly reduced **mTOR** activity.




Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM \times 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AMG-47a

Cat. No.: HY-18303

AMG-47a is a potent and orally bioavailable **lymphocyte-specific protein tyrosine kinase** (Lck) inhibitor, with an IC_{50} of 0.2 nM. AMG-47a also inhibits **VEGF2,p38 α** , **Jak3** and **MLR** and **IL-2** with IC_{50} s of 1 nM, 3 nM, 72 nM, 30 nM and 21 nM, respectively.




Purity: 98.71%
Clinical Data: No Development Reported
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

<p>AZM475271 (M475271)</p>	<p>Bosutinib (SKI-606)</p>
<p>AZM475271 is a potent and selective Src kinase inhibitor with IC₅₀ of 5 nM; no inhibitory activity on Flt3, KDR, Tie-2.</p> <p>Purity: 99.94% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</p>	<p>Bosutinib is a dual Src/Abl inhibitor with IC₅₀s of 1.2 nM and 1 nM, respectively.</p> <p>Purity: 99.96% Clinical Data: Launched Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg</p>
<p>Bosutinib D8 (SKI-606 D8)</p>	<p>Caffeic acid-pYEEIE</p>
<p>Bosutinib D8 (SKI-606 D8) is a deuterium labeled Bosutinib. Bosutinib is a dual Src/Abl inhibitor with IC₅₀s of 1.2 nM and 1 nM, respectively.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg</p>	<p>Caffeic acid-pYEEIE, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Caffeic acid-pYEEIE TFA</p>	<p>CGP77675</p>
<p>Caffeic acid-pYEEIE TFA, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>CGP77675 is a potent inhibitor of Src family kinases. CGP77675 inhibits Src, EGFR, KDR, v-Abl, and Lck with IC₅₀s of 0.02, 0.15, 1.0, 0.31, and 0.29 μM, respectively. Anticancer activity.</p> <p>Purity: >98.0% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>
<p>CH6953755</p>	<p>CSF1R-IN-2</p>
<p>CH6953755 is a potent, orally active and selective YES1 kinase (a member of the SRC family) inhibitor with an IC₅₀ of 1.8 nM. CH6953755 inhibits YES1 kinase, leading to antitumor activity against YES1 Gene -amplified cancers in vitro and in vivo.</p> <p>Purity: 99.62% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>	<p>CSF1R-IN-2 (compound 5) is an oral-active inhibitor of SRC, MET and c-FMS, with IC₅₀ values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively.</p> <p>Purity: 99.97% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>
<p>Damnacanthal</p>	<p>Dasatinib (BMS-354825)</p>
<p>Damnacanthal is an anthraquinone isolated from the root of Morinda citrifolia. Damnacanthal is a highly potent, selective inhibitor of p56^{lck} tyrosine kinase activity.</p> <p>Purity: >98.0% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Dasatinib (BMS-354825) is a potent and orally active dual Bcr-Abl and Src family tyrosine kinase inhibitor with IC₅₀s of 0.6 nM, 0.8 nM, respectively. Dasatinib also inhibits Abl, Src, Fyn, c-Kit and c-Kit^{D816V} with IC₅₀s of 2.8 nM, 79 nM and 37 nM, respectively.</p> <p>Purity: 99.85% Clinical Data: Launched Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg</p>

Dasatinib hydrochloride
(BMS-354825 hydrochloride) Cat. No.: HY-10181A

Dasatinib hydrochloride (BMS-354825 hydrochloride) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor, with K_i values of 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib hydrochloride has potent antitumor activity.


Purity: 98.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg



eCF506 Cat. No.: HY-112096

eCF506 is a highly potent and orally bioavailable inhibitor of the non-receptor tyrosine kinase Src with an IC_{50} of less than 0.5 nM.


Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



ENMD-2076 Cat. No.: HY-10987A

ENMD-2076 is a multi-targeted kinase inhibitor with IC_{50} s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFR α , respectively.


Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg



ENMD-2076 Tartrate Cat. No.: HY-10987

ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC_{50} s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFR α , respectively.


Purity: 98.59%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg



Hck-IN-1 Cat. No.: HY-125028

Hck-IN-1 (compound B9), a diphenylpyrazolo compound, is a selective Nef-dependent Hck inhibitor with IC_{50} s of 2.8 μ M, >20 μ M for Nef:Hck complex and Hck, respectively.


Purity: 98.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg



KB SRC 4 Cat. No.: HY-108488

KB SRC 4 is a potent, and highly selective c-Src inhibitor, with a K_i of 44 nM and a K_d of 86 nM, and shows no inhibition on c-Abl up to 125 μ M; KB SRC 4 has antitumor activity.


Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



KX1-004 Cat. No.: HY-18237

KX1-004 is a potent and non-ATP competitive Src-PTK inhibitor with an IC_{50} of 40 μ M. KX1-004 protects the cochlea from hazardous noise and prevents noise-induced hearing loss (NIHL).


Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg



Lavendustin C Cat. No.: HY-W013857

Lavendustin C is a potent Ca^{2+} calmodulin-dependent kinase II (CaMK II) inhibitor with an IC_{50} of 0.2 μ M. Lavendustin C inhibits EGFR-associated tyrosine kinase (IC_{50} =0.012 μ M) and pp60^{c-src(+)} kinase (IC_{50} =0.5 μ M).


Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Lck Inhibitor Cat. No.: HY-12072

Lck Inhibitor is a new class of compounds that are potent inhibitors of Lck with an IC_{50} value of 7 nM.


Purity: 98.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg





















Lck inhibitor 2 Cat. No.: HY-10644










Lck inhibitor 2 is a bis-anilopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. The IC_{50} values are 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively.

Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg




<p>Lyn peptide inhibitor</p> <p style="text-align: right;">Cat. No.: HY-P1111</p> <p>Lyn peptide inhibitor is a potent and cell-permeable inhibitor of Lyn-coupled IL-5 receptor signaling pathway, while keeping other signals intact.</p> <p style="text-align: right;"><small>Stearyl-YGYRLRRKWEKIPNP-NH₂</small></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Lyn peptide inhibitor TFA</p> <p style="text-align: right;">Cat. No.: HY-P1111A</p> <p>Lyn peptide inhibitor TFA is a potent and cell-permeable inhibitor of Lyn-coupled IL-5 receptor signaling pathway, while keeping other signals intact.</p> <p style="text-align: right;"><small>Stearyl-YGYRLRRKWEKIPNP-NH₂ (TFA salt)</small></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Masitinib (AB1010)</p> <p style="text-align: right;">Cat. No.: HY-10209</p> <p>Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC₅₀=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC₅₀s=540/800 nM), Lyn (IC₅₀=510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK.</p> <p style="text-align: right;"></p> <p>Purity: 99.94% Clinical Data: Phase 3 Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg</p>	<p>Masitinib mesylate (AB-1010 mesylate)</p> <p style="text-align: right;">Cat. No.: HY-10209A</p> <p>Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC₅₀=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC₅₀s=540/800 nM), Lyn (IC₅₀=510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK.</p> <p style="text-align: right;"></p> <p>Purity: 99.76% Clinical Data: Phase 3 Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg</p>
<p>MNS (NSC 170724; 5-(2-Nitrovinyl)benzodioxole)</p> <p style="text-align: right;">Cat. No.: HY-78263</p> <p>MNS (NSC 170724), the beta-nitrostyrene derivative, is a potent tyrosine kinase inhibitor and a broad-spectrum antiplatelet agent.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg</p>	<p>Osteogenic Growth Peptide (10-14) (OGP(10-14); Historphin)</p> <p style="text-align: right;">Cat. No.: HY-107024</p> <p>Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p>
<p>PD-089828</p> <p style="text-align: right;">Cat. No.: HY-112345</p> <p>PD-089828 is an ATP competitive inhibitor of FGFR-1, PDGFR-β and EGFR (IC₅₀s=0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of c-Src tyrosine kinase (IC₅₀=0.18 μM). PD-089828 also inhibits MAPK with an IC₅₀ of 7.1 μM.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>	<p>PD-161570</p> <p style="text-align: right;">Cat. No.: HY-100434</p> <p>PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC₅₀ of 39.9 nM and a K_i of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC₅₀ values of 310 nM, 240 nM, and 44 nM, respectively.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg</p>
<p>PD173955</p> <p style="text-align: right;">Cat. No.: HY-10395</p> <p>PD173955 is src family-selective tyrosine kinase inhibitor with IC₅₀ of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and PKC.</p> <p style="text-align: right;"></p> <p>Purity: 98.88% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg</p>	<p>Pelitinib (EKB-569; WAY-EKB 569)</p> <p style="text-align: right;">Cat. No.: HY-32718</p> <p>Pelitinib (EKB-569;WAY-EKB 569) is an irreversible inhibitor of EGFR with an IC₅₀ of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC₅₀s of 282, 800, and 1255 nM, respectively.</p> <p style="text-align: right;"></p> <p>Purity: 98.19% Clinical Data: Phase 2 Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>

<p>PF 477736 (PF 00477736)</p> <p>PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of Chk1, with a K_i of 0.49 nM, it is also a Chk2 inhibitor, with a K_i of 47 nM.</p> <p>Purity: 99.21% Clinical Data: Phase 1 Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</p>	<p>Cat. No.: HY-10032</p> 	<p>Ponatinib (AP24534)</p> <p>Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.</p> <p>Purity: 99.13% Clinical Data: Launched Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg</p>	<p>Cat. No.: HY-12047</p> 
<p>PP1 (AGL 1872; EI 275)</p> <p>PP1 is a potent, and Src family-selective tyrosine kinase inhibitor with IC_{50}s of 5 and 6 nM for Lck and Fyn, respectively.</p> <p>Purity: 98.62% Clinical Data: Phase 3 Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg</p>	<p>Cat. No.: HY-13804</p> 	<p>PP121</p> <p>PP121 is a multi-targeted kinase inhibitor with IC_{50}s of 10, 60, 12, 14, 2 nM for mTOR, DNK-PK, VEGFR2, Src, PDGFR, respectively.</p> <p>Purity: 99.08% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg</p>	<p>Cat. No.: HY-10372</p> 
<p>PP2 (AGL 1879)</p> <p>PP2 is a reversible and ATP-competitive Src family kinases inhibitor with IC_{50}s of 4 and 5 nM for Lck and Fyn, respectively.</p> <p>Purity: 98.96% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>Cat. No.: HY-13805</p> 	<p>PP58</p> <p>PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits PDGFR, FGFR and Src family activities with nanomolar IC_{50} values.</p> <p>Purity: 99.48% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</p>	<p>Cat. No.: HY-18622</p> 
<p>Rebastinib (DCC-2036)</p> <p>Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1^{WT} and Abl1^{T315I} with IC_{50} of 0.8 nM and 4 nM, also inhibits SRC, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit.</p> <p>Purity: 99.91% Clinical Data: Phase 1 Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</p>	<p>Cat. No.: HY-13024</p> 	<p>RK-24466 (KIN 001-51)</p> <p>RK-24466 (KIN 001-51) is a potent and selective Lck inhibitor; inhibits Lck (64-509) and LckCD isoforms with IC_{50}s of less than 1 and 2 nM, respectively.</p> <p>Purity: 99.14% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 1 mg, 5 mg</p>	<p>Cat. No.: HY-108318</p> 
<p>Saracatinib (AZD0530)</p> <p>Saracatinib (AZD0530) is a potent Src family inhibitor with IC_{50}s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib shows high selectivity over other tyrosine kinases.</p> <p>Purity: 99.92% Clinical Data: Phase 3 Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg</p>	<p>Cat. No.: HY-10234</p> 	<p>Scutellarein (6-Hydroxyapigenin; 4',5,6,7-Tetrahydroxyflavone)</p> <p>Scutellarin, a main active ingredient extracted from <i>Erigeron breviscapus</i> (Vant.) Hand-Mazz., has been widely used to treat acute cerebral infarction and paralysis induced by cerebrovascular diseases.</p> <p>Purity: 99.75% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg</p>	<p>Cat. No.: HY-N0752</p> 

<p>Secretin, canine</p> <p style="text-align: right;">Cat. No.: HY-P1784</p>	<p>Src Inhibitor 1 (Src Kinase Inhibitor 1; Src-I1)</p> <p style="text-align: right;">Cat. No.: HY-101053</p>
<p>Secretin, canine is an endocrine hormone that stimulates the secretion of bicarbonate-rich pancreatic fluids. Secretin, canine can regulate gastric chief cell function and paracellular permeability in canine gastric monolayers by a Src kinase-dependent pathway.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Src Inhibitor 1 is a potent and selective dual site Src tyrosine kinase inhibitor with IC_{50} values of 44 nM for Src and 88nM for Lck.</p>  <p>Purity: 99.98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg</p>
<p>Src Inhibitor 3</p> <p style="text-align: right;">Cat. No.: HY-130254</p>	<p>SU6656</p> <p style="text-align: right;">Cat. No.: HY-B0789</p>
<p>Src Inhibitor 3 is a potent, orally active c-terminal Src kinase (CSK) with IC_{50} values below 3 nM and 4 nM in CSK HTRF and Caliper assay, respectively. Src Inhibitor 3 shows the ability to increase T cell proliferation induced by T cell receptor signaling.</p>  <p>Purity: 98.61%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg</p>	<p>SU6656 is a Src family kinases inhibitor with IC_{50}s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT.</p>  <p>Purity: 96.87%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</p>
<p>TG 100572 Hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-10185</p>	<p>TG 100801</p> <p style="text-align: right;">Cat. No.: HY-10186</p>
<p>TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC_{50}s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.</p>  <p>Purity: 98.44%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg</p>	<p>TG 100801 is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration.</p>  <p>Purity: 98.60%</p> <p>Clinical Data: Phase 2</p> <p>Size: 5 mg, 10 mg, 50 mg</p>
<p>Tirbanibulin (KX2-391; KX-01)</p> <p style="text-align: right;">Cat. No.: HY-10340</p>	<p>Tirbanibulin dihydrochloride (KX2-391 dihydrochloride; KX-01 dihydrochloride)</p> <p style="text-align: right;">Cat. No.: HY-10340A</p>
<p>Tirbanibulin (KX2-391) is an inhibitor of Src that targets the peptide substrate site of Src, with GI_{50} of 9-60 nM in cancer cell lines.</p>  <p>Purity: 99.33%</p> <p>Clinical Data: Phase 3</p> <p>Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>Tirbanibulin (dihydrochloride) (KX2-391 (dihydrochloride)) is an inhibitor of Src that targets the peptide substrate site of Src, with GI_{50} of 9-60 nM in cancer cell lines.</p>  <p>Purity: 96.24%</p> <p>Clinical Data: Phase 3</p> <p>Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>
<p>Tirbanibulin Mesylate (KX2-391 Mesylate; KX01 Mesylate)</p> <p style="text-align: right;">Cat. No.: HY-10340B</p>	<p>TL02-59</p> <p style="text-align: right;">Cat. No.: HY-112852</p>
<p>Tirbanibulin Mesylate (KX2-391 Mesylate) is an inhibitor of Src that targets the peptide substrate site of Src, with GI_{50} of 9-60 nM in cancer cell lines.</p>  <p>Purity: 99.88%</p> <p>Clinical Data: Phase 3</p> <p>Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC_{50} of 0.03 nM. TL02-59 inhibits Lyn and Hck with IC_{50}s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia (AML) cell growth.</p>  <p>Purity: 99.52%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 50 mg, 100 mg</p>

Tolimidone
(MLR-1023) Cat. No.: HY-59047

Tolimidone is a potent and selective allosteric activator of **Lyn kinase** with an EC_{50} of 63 nM.



Purity: 99.98%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg

Tyrosine Kinase Peptide 1 Cat. No.: HY-P2547


Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay.

KVEKIGEGTYGVVYK

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UM-164
(DAS-DFGO-II) Cat. No.: HY-112182


UM-164 (DAS-DFGO-II) is a highly potent inhibitor of c-Src with a K_d of 2.7 nM. UM-164 also potently inhibits **p38 α** and **p38 β** .



Purity: 99.08%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

WEHI-345 analog Cat. No.: HY-100112


WEHI-345 analog is a Src inhibitor, extracted from patent WO/2012003544A1, compound example 71. Target:Src WEHI-345 (analog) is a protein kinase inhibitor.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

WH-4-023
(Dual LCK/SRC inhibitor) Cat. No.: HY-12299


WH-4-023 is a potent and selective dual Lck/Src inhibitor with IC_{50} of 2 nM/6 nM for Lck and Src kinase respectively; little inhibition on p38 α and KDR.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

XL228 Cat. No.: HY-15749


XL228 is a multi-targeted tyrosine kinase inhibitor with IC_{50} s of 5, 3.1, 1.6, 6.1, 2 nM for **Bcr-Abl**, **Aurora A**, **IGF-1R**, **Src** and **Lyn**, respectively.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

β -Hydroxyisovalerylshikonin Cat. No.: HY-N4201

Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermium radix, acts as a potent inhibitor of **protein tyrosine kinases (PTK)**, with IC_{50} s of 0.7 μ M and 1 μ M for EGFR and v-Src receptor, respectively.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg